Preoperative intravenous meloxicam for moderate-to-severe pain in the immediate post-operative period: a Phase IIIb randomized clinical trial in 55 patients undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis.
Pain Manag
; 11(1): 9-21, 2021 Jan.
Article
em En
| MEDLINE
| ID: mdl-33094682
ABSTRACT
Aim:
Evaluate safety/efficacy of intravenous meloxicam in a colorectal enhanced recovery after surgery protocol.Methods:
Adults undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis received meloxicam IV 30 mg (n = 27) or placebo (n = 28) once daily beginning 30 min before surgery.Results:
Adverse events meloxicam IV, 85%; placebo, 93%. Adverse events commonly associated with opioids 41 versus 61% - including nausea (33 vs 50%), vomiting (19 vs 18%) and ileus (4 vs 18%). Wound healing satisfaction scores (physician-rated), clinical laboratory findings and vital signs were similar in both groups. No anastomotic leaks were reported. Opioid consumption, postoperative pain intensity, length of stay and times to first bowel sound, first flatus and first bowel movement were significantly lower with meloxicam IV versus placebo. Most subjects (>92%) were satisfied with postoperative pain medication.Conclusion:
Meloxicam IV was generally well tolerated and associated with decreased opioid consumption, lower resource utilization and functional benefits. Clinical Trial Registration NCT03323385 (ClinicalTrials.gov).Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dor Pós-Operatória
/
Anti-Inflamatórios não Esteroides
/
Avaliação de Resultados em Cuidados de Saúde
/
Colectomia
/
Meloxicam
/
Protectomia
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Guideline
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pain Manag
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos